ArticleBiomedicines2021
Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids.Cancer biology & therapy · 2026Article
- Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.Journal of experimental & clinical cancer research : CR · 2025Article
- Endocrine cancer organoids in basic and translational medical research.Science China. Life sciences · 2025Review
- Organoid models established from primary tumors and patient-derived xenograft tumors reflect platinum sensitivity of ovarian cancer patients.BMC cancer · 2025Article
- Development and Applications of Organoids in Gynecological Diseases.Stem cell reviews and reports · 2025Review
- Article
- Organoid development and applications in gynecological cancers: the new stage of tumor treatment.Journal of nanobiotechnology · 2025Review
- Patient-derived cell lines unveil COL1A2 as a predictor of docetaxel resistance in breast cancer.Frontiers in oncology · 2025Article
- In vitro drug testing using patient-derived ovarian cancer organoids.Journal of ovarian research · 2024Article
- Organoid modeling meets cancers of female reproductive tract.Cell death discovery · 2024Review
- Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.Experimental & molecular medicine · 2024Review
- Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer.Cancers · 2024Article
- Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.Journal of cancer research and clinical oncology · 2024Review
- Cancer organoids: A platform in basic and translational research.Genes & diseases · 2024Review
- Research progress on the application of organoids in gynecological tumors.Frontiers in pharmacology · 2024Review
- Three possible diagnostic biomarkers for gastric cancer: miR-362-3p, miR-362-5p and miR-363-5p.Biomarkers in medicine · 2024Article
- Advances and challenges in the origin and evolution of ovarian cancer organoids.Frontiers in oncology · 2024Review
- Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.Cancer medicine · 2023Review
- Bioengineered 3D Ovarian Models as Paramount Technology for Female Health Management and Reproduction.Bioengineering (Basel, Switzerland) · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The development of patient-derived tumor organoids (TOs) from an epithelial ovarian cancer tumor obtained at the time of primary or interval debulking surgery has the potential to play an important role in precision medicine. Here, we utilized TOs to test front-line chemotherapy sensitivity and to investigate genomic drivers of carboplatin resistance. We developed six high-grade, serous epithelial ovarian cancer tumor organoid lines from tissue obtained during debulking surgery (two neoadjuvant-carboplatin-exposed and four chemo-naïve). Each organoid line was screened for sensitivity to carboplatin at four different doses (100, 10, 1, and 0.1 µM). Cell viability curves and resultant EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.